Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT07004179
Starting soon Not applicable

Implementation of a Diabetic Foot Prevention Strategy in Primary Care (iMplanta Study)

NCT07004179 · tracked via the Priya Life Science Spain tracker
Phase
Not applicable
Started
2025-09-01
Last updated
2025-06-29

Condition(s) studied

Diabetic Foot DiseaseDiabetic Foot Ulcer (DFU)

Investigational drug(s) / intervention(s)

Implementation strategy developed using the Implementation Mapping model to enhance the effective integration of the Protocol for Assistance to People with Diabetic FootSham Comparator

Implementation strategy developed using the Implementation Mapping model to enhance the effective integration of the Protocol for Assistance to People with Diabetic Foot: The intervention will be based on the Implementation Mapping methodology (IM). This model is based on the Intervention Mapping. IM consists of several specific tasks: 1. Conduct an assessment of needs and identification of programme adopters and implementers through a review of qualitative or mixed studies assessing the perceptions of both patients and professionals regarding DF prevention as well as individual semi-structured interviews with patients, health professionals and management staff 2. Indicate adoption and implementation outcomes and action objectives, identifying determinants and create matrices of change; this process will allow for the identification of determinants, which are those factors that influence the actions will be implemented 3. Select theoretical methods and select or design implementation strategies using the ERIC model (Expert Recommendations for Implementing Change) 4. Produce implementation protocols and materials 5. Evaluate implementation results

Sham Comparator: Usual care: No systematic implementation of the protocol based on the prevention of foot at risk, ulcer treatment and screening of the risk of diabetic foot ulcer for referral to hospital care.

Study summary

The goal of this two-arm cluster randomised controlled trial (RCT) is to evaluate the effectiveness of a new implementation strategy based on the ImM model for the Protocol of assistance to the person with diabetic foot (PAPDF) of the Balearic Islands Health Service in reducing complications of diabetic foot, compared to the current implementation strategy, in the primary care centers of Majorca. As secondary objectives we aim 1. To determine the reach of the implementation strategy in the GAPM primary care centers, 2.To compare the effectiveness of the PAPDF versus usual care in preventing diabetic foot complications, 3. To identify the number of healthcare professionals adhering to the implementation strategy and 4. To assess the sustainability of the implementation strategy over time.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of type 1 or type 2 diabetes mellitus. * Aged 18 years or older. * Attending nursing consultations at participating primary care centers during the study period. Exclusion Criteria: * Patients with gestational diabetes. * Patients with diabetic foot ulcers prior to the start of the study. * Patients with lower limb amputations prior to the start of the study.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Gerència d'Atenció Primària de Mallorca, Palma De Mallorca, Balearic Islands 07002 Palma de Mallorca Balearic Islands

More University of the Balearic Islands trials in Spain

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07004179 on ClinicalTrials.gov ↗ ← All trials in Spain